Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study

Completed

• Conditions: Diabetes

• Registration Number: NCT01306110
• Lead Sponsor: Association HGE CHU Bordeaux Sud

Brief Summary

The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.

Detailed Description

Patients with diabetes are at risk for nonalcoholic fatty liver disease (NAFLD) leading to advanced fibrosis, cirrhosis, and liver cancer. However, liver fibrosis screening in this large population needs non-invasive methods. Recently, FibroScan was shown to be a good method for the diagnosis of advanced fibrosis in NAFLD patients. We examined the efficacy of a screening strategy with a noninvasive fibrosis biomarker (FibroTest) and transient elastography (FibroScan) in patients with diabetes.

Study Timeline

• Study Start: 2007-06
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Study First Submitted: 2011-02-28
• Study First Submitted QC: 2011-02-28
• Study First Posted: 2011-03-01
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-07
• Last Update Posted: 2016-01-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 277

Inclusion Criteria

• Male or female subjects
• More than 18 years of age
• Patients with Diabetes
• Written informed consent

Exclusion Criteria

• Patients refusing to participate to the study and to provide written informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Service Hepato-Gastroentérologie Hopital Haut-Leveque; 🇫🇷 Pessac, France